Clinical trial · Interventional
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application. 2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thalidomide+cetuximab+FOLFOX/FOLFIRI | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Test group
- description
- Thalidomide+cetuximab+FOLFOX/FOLFIRI
- interventionNames
- Drug: Thalidomide+cetuximab+FOLFOX/FOLFIRI
- type
- NO_INTERVENTION
- label
- control group
- description
- cetuximab+FOLFOX/FOLFIRI
Primary outcomes (1)
- measure
- ETS
- timeFrame
- 8 weeks
- description
- Early tumor shrinkage
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing; 2. Physical state is good: PS 0-2; 3. Expected survival of more than 3 months; 4. Aged 18-75 years old; 5. Have not received systematic chemotherapy before; 6. Did not receive cetuximab treatment; 7. Liver, kidney and bone marrow functions are basically normal; 8. The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks; 9. Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent. Exclusion Criteria: 1. Patients with severe dysfunction of vital organs (heart, liver, kidney); 2. Patients with other malignant tumors; 3. Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test); 4. In the active phase of acute or chronic infectious diseases; 5. People with a clear history of drug allergy or allergic constitution; 6. Patients participating in other clinical trials; 7. Other conditions in which the patient was considered inappropriate to participate in the study.
References
Publications (0)
Data not yet available